aa |
Amino acid |
ACLY |
Adenosine triphosphate-citrate lyase |
ADP |
Adenosine Diphosphate |
CVD |
Cardiovascular disease |
CHD |
Congenital heart disease |
Da |
Dalton |
DALYS |
Disability-Adjusted Life Years |
DHCR24 |
Dehydrocholesterol reductase24 |
EBP |
Emopamil binding protein |
EGF-A |
Epidermal Growth Factor like-domain A |
EMA |
European Medicines Agency |
FDA |
Food and Drug Administration |
GI |
Gastrointestinal |
h |
Human |
HMG-CoA |
3-Hydroxy-3-Methyl Glutaryl Coenzyme A |
IDL |
Intermediate-density lipoprotein |
IR |
Immediate Release |
LDL |
Low-density lipoprotein |
mAb |
Monoclonal antibody |
MHRA |
Medicines and Healthcare products Regulatory Agency, UK |
mRNA |
Messenger Ribonucleic Acid |
MW |
Molecular weight |
OSC |
Oxidosqualene cyclase |
PCSK9 |
Proprotein Convertase Subtilisin Kexin9 |
RISC |
RNA-induced silencing complex |
SNAC |
Sodium N-(8-[2-hydroxybenzoyl] amino) caprylate |
SQLE |
Squalene epoxidase |
SQS |
Squalene synthase |
tBu |
Tertiary butyl |
THPBs |
Tetrahydroproto-berberines |
VLDL |
Very low-density lipoprotein |